通过在类似病毒的粒子上显示抗原来增强对阿片类药物的保护性抗体
Fatemeh Shafieichaharberoud1,2, Shuyao Lang1,2, Connor Whalen3
1Department of Chemistry, Michigan State University, 578 S. Shaw Lane, East Lansing, Michigan 48824, United States.
Bioconjugate chemistry
|December 19, 2023
概括
使用菌体载体 (mQβ-6-AmHap) 的新型疫苗有效地产生了对海洛因及其衍生物的长期抗体,显示出对抗阿片类药物使用障碍 (OUD) 的潜力. 这种疫苗在小鼠中减少了吗啡的作用.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 疫苗开发 疫苗开发
背景情况:
- 阿片类药物使用障碍 (OUD) 是一个重大的公共卫生挑战,因过量服用死亡人数上升而显著.
- 疫苗接种策略提供了一种有希望的补充方法来对抗OUD.
- 有效的疫苗需要诱导特定于向药物的高亲和抗体.
研究的目的:
- 评估一种新型疫苗结合物mQβ-6-AmHap对抗阿片类药物使用障碍的免疫性和有效性.
- 评估病毒样粒子突变细菌Qβ (mQβ) 作为模仿海洛因的小分子 hapten 的载体的潜力.
主要方法:
- 开发一种使用mQβ作为海洛因模仿基-6-AmHap的载体的合物.
- 用mQβ-6-AmHap对小鼠进行免疫接种,并与疹毒素-6-AmHap合剂进行比较.
- 测量IgG抗体标位,抗体结合特异性和评估疫苗对小鼠吗啡诱导行为的影响.
主要成果:
- 与疹毒素合物相比,mQβ-6-AmHap合物诱导了针对6-AmHap的IgG抗体水平显著更高.
- 高抗-6-AmHap抗体标位在免疫接种后至少持续600天.
- 诱导的抗体显示出与海洛因衍生品的特定结合,同时与OUD药物相互作用最小.
- 接种疫苗有效地减少了吗啡对小鼠行走和反感受的影响.
结论:
- mQβ-6-AmHap结合物是一种强大的免疫原,能够引起针对海洛因和相关化合物的持久性,特异性抗体.
- 这种疫苗策略表明了减轻阿片类药物的有害影响和打击OUD的翻译潜力.
更多相关视频
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
2.6K
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.7K
相关概念视频
Immune Response Against Viral Pathogens
789
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
789
Vaccinations
44.6K
Overview
44.6K
Hybridoma Technology
14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K
Cross-reactivity
31.1K
Overview
31.1K
